Century Therapeutics, Inc. (IPSC) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.26
+19% vs avg
5yr avg: 1.06
30Y Low0.5·High2.2
ROE
↑
-6.0%
↓+87% vs avg
5yr avg: -47.8%
30Y Low-73%·High-6%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IPSC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Century Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $202M | $86M | $79M | $197M | $296M | $872M | — | — |
| Enterprise Value | $181M | $65M | $75M | $198M | $261M | $841M | — | — |
| P/E Ratio → | -16.50 | — | — | — | — | — | — | — |
| P/S Ratio | 1.85 | 0.79 | 12.06 | 88.11 | 56.99 | — | — | — |
| P/B Ratio | 1.26 | 0.54 | 0.49 | 1.07 | 0.98 | 2.20 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | 21.09 | — | — | — |
P/E links to full P/E history page with 30-year chart
IPSC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.59 | 11.36 | 88.49 | 50.29 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
IPSC Profitability
Margins and return-on-capital ratios measuring operating efficiency
Century Therapeutics, Inc. earns an operating margin of -15.8%. Operating margins have expanded from -6556.9% to -15.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -6.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | -15.8% | -15.8% | -2096.5% | -6556.9% | -2574.2% | — | — | — |
| Net Profit Margin | -8.8% | -8.8% | -1920.9% | -6115.1% | -2518.4% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -6.0% | -6.0% | -73.1% | -56.1% | -37.5% | -66.1% | — | — |
| ROA | -3.3% | -3.3% | -35.5% | -32.3% | -28.3% | -35.2% | -54.2% | -269.3% |
| ROIC | -8.8% | -8.8% | -60.5% | -48.5% | -31.7% | -56.3% | — | — |
| ROCE | -8.1% | -8.1% | -48.8% | -36.7% | -30.5% | -36.7% | -53.9% | -22.8% |
IPSC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $62M exceeds total debt of $40M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.33 | 0.26 | 0.16 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.14 | -0.03 | 0.00 | -0.12 | -0.08 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -271.38 | — | -74.42 | -129.07 | — |
Net cash position: cash ($62M) exceeds total debt ($40M)
IPSC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Century Therapeutics, Inc.'s current ratio of 5.97x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 9.92x to 5.97x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.97 | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 |
| Quick Ratio | 5.97 | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 | 6.51 | 28.10 |
| Cash Ratio | 5.79 | 5.79 | 1.46 | 9.68 | 10.58 | 14.24 | 6.25 | 27.23 |
| Asset Turnover | — | 0.49 | 0.02 | 0.01 | 0.01 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 84.20 | 108.60 | 54.76 | — | — | — |
IPSC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Century Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $87M | $79M | $59M | $58M | $55M | $55M | $55M |
Peer Comparison
Compare IPSC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IPSCYou | $202M | -16.5 | — | — | — | -15.8% | -6.0% | -8.8% | — |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 CELC | $6B | -46.2 | — | — | — | — | -87.5% | -50.3% | — |
 IOVA | $1B | -3.3 | — | — | 97.2% | -153.1% | -55.5% | -48.9% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See IPSC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IPSC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IPSC vs FATE
Side-by-side business, growth, and profitability comparison vs Fate Therapeutics, Inc..
Start ComparisonIPSC — Frequently Asked Questions
Quick answers to the most common questions about buying IPSC stock.
What is Century Therapeutics, Inc.'s P/E ratio?
Century Therapeutics, Inc.'s current P/E ratio is -16.5x. This places it at the 50th percentile of its historical range.
What is Century Therapeutics, Inc.'s ROE?
Century Therapeutics, Inc.'s return on equity (ROE) is -6.0%. The historical average is -47.8%.
Is IPSC stock overvalued?
Based on historical data, Century Therapeutics, Inc. is trading at a P/E of -16.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Century Therapeutics, Inc.'s profit margins?
Century Therapeutics, Inc. has -15.8% operating margin.